Trial · NCT02109445
Results by group41
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 41
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | 2 | participants | ||
| Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | All-causality TEAEs | 3 | participants | |
| Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | Treatment-related TEAEs | 3 | participants | |
| Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | Grade 3 or 4 TEAEs | 3 | participants | |
| Number of Participants With Laboratory Abnormalities in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | 3 | participants | ||
| Number of Participants With Worsening QTc Results in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | NA | participants | ||
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUClast for PF-03084014 on Day 3 (n=3) | 1122 | Geometric Coefficient of Variation 913 | nanogram*hour/milliliter (ng*hr/mL) |
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUClast for PF-03084014 on Day 15 (n=1) | 1770 | Geometric Coefficient of Variation NA | nanogram*hour/milliliter (ng*hr/mL) |
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUCinf for nab-paclitaxel on Day 1 (n=3) | 5774 | Geometric Coefficient of Variation 11 | nanogram*hour/milliliter (ng*hr/mL) |
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUClast for nab-paclitaxel on Day 1 (n=3) | 5185 | Geometric Coefficient of Variation 9 | nanogram*hour/milliliter (ng*hr/mL) |
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUCinf for nab-paclitaxel on Day 15 (n=1) | 5050 | Geometric Coefficient of Variation NA | nanogram*hour/milliliter (ng*hr/mL) |
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUClast for nab-paclitaxel on Day 15 (n=1) | 4600 | Geometric Coefficient of Variation NA | nanogram*hour/milliliter (ng*hr/mL) |
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUCinf for gemcitabine on Day 1 (n=3) | 5316 | Geometric Coefficient of Variation 172 | nanogram*hour/milliliter (ng*hr/mL) |
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUClast for gemcitabine on Day 1 (n=3) | 5262 | Geometric Coefficient of Variation 176 | nanogram*hour/milliliter (ng*hr/mL) |
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUCinf for gemcitabine on Day 15 (n=1) | 2510 | Geometric Coefficient of Variation NA | nanogram*hour/milliliter (ng*hr/mL) |
| Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | AUClast for gemcitabine on Day 15 (n=1) | 2500 | Geometric Coefficient of Variation NA | nanogram*hour/milliliter (ng*hr/mL) |
| Maximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | Cmax for PF-03084014 on Day 3 (n=3) | 527.3 | Geometric Coefficient of Variation 710 | nanogram/milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | Cmax for PF-03084014 on Day 15 (n=1) | 943.0 | Geometric Coefficient of Variation NA | nanogram/milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | Cmax for nab-paclitaxel on Day 1 (n=3) | 6023 | Geometric Coefficient of Variation 6 | nanogram/milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 1 | PF-03084014 + Nab-Paclitaxel + Gemcitabine | Cmax for nab-paclitaxel on Day 15 (n=1) | 5140 | Geometric Coefficient of Variation NA | nanogram/milliliter (ng/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02109445/results